Cargando…

Exosomal MicroRNA Levels Associated with Immune Checkpoint Inhibitor Therapy in Clear Cell Renal Cell Carcinoma

Immunotherapy with immune checkpoint inhibitors (ICIs) has shown high efficiency in clear cell renal cell carcinoma (ccRCC) treatment. However, the response to therapy among patients varies greatly. Modern studies demonstrate the high potential of exosomal miRNAs as diagnostic and prognostic markers...

Descripción completa

Detalles Bibliográficos
Autores principales: Ivanova, Elizaveta, Asadullina, Dilara, Gilyazova, Gulshat, Rakhimov, Radmir, Izmailov, Adel, Pavlov, Valentin, Khusnutdinova, Elza, Gilyazova, Irina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045368/
https://www.ncbi.nlm.nih.gov/pubmed/36979782
http://dx.doi.org/10.3390/biomedicines11030801
_version_ 1784913586360942592
author Ivanova, Elizaveta
Asadullina, Dilara
Gilyazova, Gulshat
Rakhimov, Radmir
Izmailov, Adel
Pavlov, Valentin
Khusnutdinova, Elza
Gilyazova, Irina
author_facet Ivanova, Elizaveta
Asadullina, Dilara
Gilyazova, Gulshat
Rakhimov, Radmir
Izmailov, Adel
Pavlov, Valentin
Khusnutdinova, Elza
Gilyazova, Irina
author_sort Ivanova, Elizaveta
collection PubMed
description Immunotherapy with immune checkpoint inhibitors (ICIs) has shown high efficiency in clear cell renal cell carcinoma (ccRCC) treatment. However, the response to therapy among patients varies greatly. Modern studies demonstrate the high potential of exosomal miRNAs as diagnostic and prognostic markers in oncopathology. This study aimed to evaluate exosomal miRNA expression profiles of miRNAs-144, -146a, -149, -126, and -155 in patients with clear cell renal cell carcinoma treated with immune checkpoint inhibitors. The study included 35 patients whose venous blood samples were taken before and after ICI therapy. Expression analysis was performed using real-time quantitative PCR. It was demonstrated that the level of microRNA-146a increased after therapy (median(IQR) 12.92(4.06–18.90)) compared with the level before it (median(IQR) 7.15(1.90–10.50); p-value = 0.006). On the contrary, microRNA-126 was reduced after therapy with immune checkpoint inhibitors (median(IQR) 0.85(0.55–1.03) vs. 0.48(0.15–0.68) before and after therapy, respectively; p-value = 0.0001). In addition, miRNA-146a expression was shown to be reduced in patients with a higher grade of immune-related adverse events (p-value = 0.020). The AUC value for the miRNA-146a and miRNA-126 combination was 0.752 (95% CI 0.585–0.918), with the sensitivity at 64.3% and the specificity at 78.9%. Thus, while it can be assumed that miRNA-146a and miRNA-126 can be used as predictors for ICI therapy effectiveness, additional in-depth studies are required.
format Online
Article
Text
id pubmed-10045368
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100453682023-03-29 Exosomal MicroRNA Levels Associated with Immune Checkpoint Inhibitor Therapy in Clear Cell Renal Cell Carcinoma Ivanova, Elizaveta Asadullina, Dilara Gilyazova, Gulshat Rakhimov, Radmir Izmailov, Adel Pavlov, Valentin Khusnutdinova, Elza Gilyazova, Irina Biomedicines Article Immunotherapy with immune checkpoint inhibitors (ICIs) has shown high efficiency in clear cell renal cell carcinoma (ccRCC) treatment. However, the response to therapy among patients varies greatly. Modern studies demonstrate the high potential of exosomal miRNAs as diagnostic and prognostic markers in oncopathology. This study aimed to evaluate exosomal miRNA expression profiles of miRNAs-144, -146a, -149, -126, and -155 in patients with clear cell renal cell carcinoma treated with immune checkpoint inhibitors. The study included 35 patients whose venous blood samples were taken before and after ICI therapy. Expression analysis was performed using real-time quantitative PCR. It was demonstrated that the level of microRNA-146a increased after therapy (median(IQR) 12.92(4.06–18.90)) compared with the level before it (median(IQR) 7.15(1.90–10.50); p-value = 0.006). On the contrary, microRNA-126 was reduced after therapy with immune checkpoint inhibitors (median(IQR) 0.85(0.55–1.03) vs. 0.48(0.15–0.68) before and after therapy, respectively; p-value = 0.0001). In addition, miRNA-146a expression was shown to be reduced in patients with a higher grade of immune-related adverse events (p-value = 0.020). The AUC value for the miRNA-146a and miRNA-126 combination was 0.752 (95% CI 0.585–0.918), with the sensitivity at 64.3% and the specificity at 78.9%. Thus, while it can be assumed that miRNA-146a and miRNA-126 can be used as predictors for ICI therapy effectiveness, additional in-depth studies are required. MDPI 2023-03-06 /pmc/articles/PMC10045368/ /pubmed/36979782 http://dx.doi.org/10.3390/biomedicines11030801 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ivanova, Elizaveta
Asadullina, Dilara
Gilyazova, Gulshat
Rakhimov, Radmir
Izmailov, Adel
Pavlov, Valentin
Khusnutdinova, Elza
Gilyazova, Irina
Exosomal MicroRNA Levels Associated with Immune Checkpoint Inhibitor Therapy in Clear Cell Renal Cell Carcinoma
title Exosomal MicroRNA Levels Associated with Immune Checkpoint Inhibitor Therapy in Clear Cell Renal Cell Carcinoma
title_full Exosomal MicroRNA Levels Associated with Immune Checkpoint Inhibitor Therapy in Clear Cell Renal Cell Carcinoma
title_fullStr Exosomal MicroRNA Levels Associated with Immune Checkpoint Inhibitor Therapy in Clear Cell Renal Cell Carcinoma
title_full_unstemmed Exosomal MicroRNA Levels Associated with Immune Checkpoint Inhibitor Therapy in Clear Cell Renal Cell Carcinoma
title_short Exosomal MicroRNA Levels Associated with Immune Checkpoint Inhibitor Therapy in Clear Cell Renal Cell Carcinoma
title_sort exosomal microrna levels associated with immune checkpoint inhibitor therapy in clear cell renal cell carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045368/
https://www.ncbi.nlm.nih.gov/pubmed/36979782
http://dx.doi.org/10.3390/biomedicines11030801
work_keys_str_mv AT ivanovaelizaveta exosomalmicrornalevelsassociatedwithimmunecheckpointinhibitortherapyinclearcellrenalcellcarcinoma
AT asadullinadilara exosomalmicrornalevelsassociatedwithimmunecheckpointinhibitortherapyinclearcellrenalcellcarcinoma
AT gilyazovagulshat exosomalmicrornalevelsassociatedwithimmunecheckpointinhibitortherapyinclearcellrenalcellcarcinoma
AT rakhimovradmir exosomalmicrornalevelsassociatedwithimmunecheckpointinhibitortherapyinclearcellrenalcellcarcinoma
AT izmailovadel exosomalmicrornalevelsassociatedwithimmunecheckpointinhibitortherapyinclearcellrenalcellcarcinoma
AT pavlovvalentin exosomalmicrornalevelsassociatedwithimmunecheckpointinhibitortherapyinclearcellrenalcellcarcinoma
AT khusnutdinovaelza exosomalmicrornalevelsassociatedwithimmunecheckpointinhibitortherapyinclearcellrenalcellcarcinoma
AT gilyazovairina exosomalmicrornalevelsassociatedwithimmunecheckpointinhibitortherapyinclearcellrenalcellcarcinoma